Endothelial Regulation of Drug Transport in a 3D Vascularized Tumor Model

Kristina Haase1, Giovanni S Offeddu1, Mark R Gillrie2

  • 1Massachusetts Institute of Technology, Massachusetts, 02139, USA.

Advanced Functional Materials
|March 11, 2021
PubMed

Insights

A novel 3D vascularized tumor-on-chip model improves cancer drug delivery prediction by mimicking the tumor microenvironment (TME). This platform enhances understanding of drug transport and efficacy, offering a more accurate preclinical assessment for cancer treatments.

Area of Science:

  • Biomedical Engineering
  • Cancer Research
  • Drug Delivery Systems

Background:

  • Pre-clinical cancer models often fail to predict drug efficacy due to lacking a physiological tumor microenvironment (TME).
  • The TME, including vasculature and stroma, significantly influences drug delivery and therapeutic response.
  • Current models do not adequately represent the complex interactions governing drug transport in vivo.

Purpose of the Study:

  • To develop and utilize a 3D vascularized tumor-on-chip platform for studying drug delivery within a relevant TME.
  • To investigate the impact of pathophysiological changes in a vascularized TME on drug transport and efficacy.
  • To compare drug response in a vascularized model versus simpler systems.

Main Methods:

  • Fabrication of a 3D tumor-on-chip model with a perfusable vasculature network.
  • Introduction of tumor spheroids (Skov3 and A549) to induce localized pathophysiological changes.
  • Assessment of paclitaxel (Taxol) uptake using diffusivity, efflux assays, and fluorescence measurements.
  • Evaluation of tumor response, including shrinkage and CD44 expression, in vascularized versus non-vascularized models.

Main Results:

  • The 3D vascularized model demonstrated localized pathophysiological effects, altering vessel density and barrier function.
  • Paclitaxel uptake and accumulation were influenced by vascular and stromal components within the TME.
  • Vascularized tumors showed distinct responses to paclitaxel, including shrinkage and altered CD44 expression, compared to simpler models.
  • The model allowed for spatially resolved examination of tumor-associated endothelial dysfunction.

Conclusions:

  • The 3D vascularized tumor-on-chip model provides a more physiologically relevant platform for studying drug delivery in cancer.
  • This system enhances the prediction of in vivo drug distribution by incorporating TME factors.
  • The model holds potential for improving the accuracy of preclinical drug efficacy testing for cancer therapies.